Akèy › Kansè nan tete › Kalifòni › San Francisco
Etid klinik pou Kansè nan tete nan San Francisco, CA
43 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote San Francisco (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, San Francisco
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- Kaiser Permanente-San Francisco, San Francisco
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Ap rekriteFaz 2
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, San Francisco
- Clinical Trial Site, San Francisco
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Kaiser Permanente, San Francisco
- UCSF Medical Center at Mission Bay, San Francisco
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Ap rekriteVolontè an sante akeyi
- University of California San Francisco, San Francisco
Pulsed Electric Field Ablation for Metastatic Breast Cancer
Ap rekrite
- University of California San Francisco, San Francisco
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- UCSF Zuckerberg SF General, San Francisco
- University of California, San Francisco (UCSF), San Francisco
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Ap rekriteFaz 1
- UCSF Medical Center at Mission Bay, San Francisco
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Ap rekriteFaz 1/2
- UCSF Helen Diller Family CCC, San Francisco
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Ap rekriteFaz 1/2
- University of California, San Francisco, San Francisco
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of California-San Fransisco, San Francisco
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Ap rekriteEtid obsèvasyon
- University of California, San Francisco, San Francisco
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Ap rekriteFaz 2
- University of San Francisco, San Francisco
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Ap rekriteFaz 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Ap rekriteFaz 2
- University of California San Francisco, San Francisco
Generative AI Patient Education Module for Breast Oncology
Ap rekrite
- University of California, San Francisco, San Francisco
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer
Ap rekriteEtid obsèvasyon
- University of California, San Francisco, San Francisco
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
Ap rekriteFaz 3
- University of California at San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- University of California San Francisco (UCSF), San Francisco
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Ap rekriteFaz 2
- UCSF Medical Center-Mission Bay/Benioff Children's Hospital, San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Ap rekriteFaz 2
- University of California San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction
Ap rekriteEtid obsèvasyon
- University of California, San Francisco
Microbiome and Association With Implant Infections
Ap rekriteFaz 2
- University of California, San Francisco, San Francisco
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Kaiser Permanente-San Francisco, San Francisco
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Ap rekriteFaz 2
- University of California San Francisco (Data collection only), San Francisco
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Ap rekriteFaz 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- University of California San Francisco, San Francisco
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Ap rekrite
- UCSF Breast Care Center, San Francisco
Patient Care Outreach, Navigation, Technology and Support 2.0
Ap rekrite
- Zuckerberg San Francisco General Hospital, San Francisco
- University of California, San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of California, San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, San Francisco
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- UCSF Breast Care Center, San Francisco
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan San Francisco
- Kansè pwostat45 etid
- Kansè Poumon ki pa ti selil36 etid
- Kansè (tout kalite)35 etid
- Ensifizyans kadyak29 etid
- Kansè Metastatik28 etid
- Kansè poumon22 etid
- Melanom22 etid
- Kansè pankreyas20 etid
- Kansè ovè19 etid
- Kansè kolorektal18 etid
- Maladi kadyovaskilè18 etid
- Gliyoblastòm17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.